

**Pediatric Grand Rounds – Tulsa SCM
Course No. 22D30**

**Tuesday, January 11, 2022
12:30 – 1:30 pm**

***** Zoom Teleconference Meeting *****

“When to Worry? What Pediatric Dermatology Conditions to Refer?”

Presented by:
Kimberly A. Horii, MD, Children's Mercy Hospital

My lectureship is technically the Walter Tunnessen Visiting Professor Program sponsored by the AAP Section on Dermatology

Professional Practice Gap

1. Providers may not be aware of which infantile hemangiomas may require workup or treatment by a specialist
2. Some providers are not aware of which patients with melanocytic nevi should be referred to a subspecialist for evaluation and monitoring
3. Skin conditions are common in children, but many primary care providers have not been adequately trained to recognize and treat life threatening rashes

Learning objectives - Upon completion of this session, participants will improve their competence and performance by being able to:

1. Identify which high risk infantile hemangiomas should be referred to a specialist.
2. Identify worrisome diaper rashes that warrant evaluation by a specialist.
3. Identify which patients with nevi should be referred to a specialist.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

Equal Opportunity Statement: The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link.ou.edu/reportingform.

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit www.ou.edu/eoo.

Accommodation Statement: For accommodations, please contact Sheryl Hayes at 918-660-3395 or Sheryl-hayes@ouhsc.edu.

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Planner and Presenter Disclosure: It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

Acknowledgement of Commercial and In-Kind Support: **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity. An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
This activity received no commercial or in-kind support.

Disclosure & Mitigation Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

| Role | First Name | Last Name | Nature of Financial Relationship | | |
|---|-------------|------------|--|------------------------------|----------------|
| | | | Ineligible Company | What was received? | For what role? |
| Planning Member | Michelle K. | Escala, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
| Course Contact | Sheryl K. | Hayes | I have no financial relationships or affiliations with ineligible companies to disclose. | | |
| Presenter | Kimberly | Horii, MD | American Academy of Pediatrics | Honoraria | Speaker |
| | | | UpToDate | Royalties/Patent Beneficiary | Owner |
| | | | NEJM Knowledge+ | Paid Consultant | Consultant |
| <p>Presenter: The conflict was resolved by Dr. Horii stating that the presentation does not have any relevance to the ineligible companies. The AAP does not meet the definition of an ineligible company therefore there is no conflict to mitigate. Dr. Horii agreed to provide clinical recommendations based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.</p> | | | | | |
| Planning Member | Keith D. | Mather, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | |